Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Time to Sell?

Shares of Genmab A/S (NASDAQ:GMAB) gapped down prior to trading on Tuesday . The stock had previously closed at $19.58, but opened at $19.09. Genmab A/S shares last traded at $18.95, with a volume of 227,258 shares traded.

Analysts Set New Price Targets

GMAB has been the subject of several research analyst reports. Truist Financial decreased their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Finally, Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Trading Down 2.7 %

The stock has a market capitalization of $12.60 billion, a P/E ratio of 10.93, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company has a 50-day moving average price of $20.87 and a 200 day moving average price of $21.79.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC acquired a new stake in shares of Genmab A/S in the 4th quarter worth $3,525,000. HighTower Advisors LLC purchased a new position in Genmab A/S during the 3rd quarter worth $273,000. Verition Fund Management LLC acquired a new position in Genmab A/S during the 3rd quarter valued at about $709,000. Finally, FMR LLC raised its stake in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after buying an additional 33,076 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.